Videos

Lori Wirth, MD, describes the available treatment options for patients with advanced RAI-R-DTC who progress after first-line treatment with lenvatinib.

Dr Lori Wirth highlights exciting clinical trials in advanced RAI-R-DTC and investigational agents to look out for in the future.

Lori Wirth, MD, provides a brief overview of advanced radioactive iodine-refractory differentiated thyroid cancer, or RAI-R-DTC.

Cyrus M. Kahn, MD, discusses the evolution of the treatment landscape for patients with mantle cell lymphoma.

Robert J. Soiffer, MD, discusses the use of transplant in various hematologic malignancies.

A lung cancer expert describes the common adverse events he sees with immunotherapy in mNSCLC, and the available management strategies.

Edward B. Garon, MD, MS, shares his biomarker testing protocols for patients with NSCLC and highlights the most important biomarkers for guiding therapy.

Dr Edward B. Garon explains the rationale for treating patients with mNSCLC with a frontline combination of chemotherapy and immune checkpoint inhibitors.

Closing the program, Edward B. Garon, MD, MS, shares his view on the implications of recent mNSCLC data in clinical practice, and the unmet needs the field must focus on in the future.

Dr Garon continues with an explanation of the updated analysis of the POSEIDON trial presented at the 2022 World Conference on Lung Cancer.

A key opinion leader reviews the study design and efficacy and safety outcomes of the POSEIDON trial investigating durvalumab + tremelimumab + chemotherapy for treatment of mNSCLC.

Erika P. Hamilton, MD, discusses the purpose of a safety follow-up analysis for the DESTINY-Breast03 trial of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.

Alexander Spira, MD, PhD, FACP, discusses the rationale for combining amivantamab-vmjw and lazertinib for the treatment of relapsed or refractory EGFR-mutant non–small cell lung cancer.

In the first installment of this series, Joshua Sabari, MD, provides an overview on the use of chemotherapy for first-line treatment of NSCLC, and discusses how the more recent availability of PD-1/PD-L1– and CTLA-4–targeted immunotherapy is changing the field.

David Morris, MD, FACS, discusses how PSMA PET imaging may impact targeted therapies for prostate cancer in the future.

Bradley A. McGregor, MD, discusses current and future second-line therapy options following frontline tyrosine kinase inhibitor and immunotherapy for patients with advanced renal cell carcinoma.

Dr Bardia provides his opinion on the current state of the ER+/HER2- treatment landscape and where elacestrant belongs in the current treatment paradigm.

Joshua J. Meeks, MD, discusses investigational targets in the bladder cancer space.

Expert panelists review the case of a 22-year-old woman diagnosed with BPDCN and consider the role of first-line chemotherapy in this setting.

Before closing out their review of polycythemia vera management, expert hematologist-oncologists highlight novel therapies in the pipeline.

Closing out their discussion on the first patient case of BPDCN, panelists consider which factors best inform the optimal selection of frontline therapy.

Considerations for the selection of optimal therapy in patients with polycythemia vera, and how these novel agents may be sequenced in the event of disease progression.

Toni K. Choueiri, MD, discusses a key next step for using pembrolizumab in the treatment of renal cell carcinoma.

According to Allan Pickens, MD, surgery outcomes differ in minority patients and oncology surgeons are researching the issue.

Taking a closer look at the EMERALD trial, Dr Bardia shares key efficacy outcomes from the sub-group analyses 1) of patients with no prior chemotherapy and 2) comparing elacestrant to fulvestrant or AI.

Matthew P. Goetz, MD, discusses the background of the ELAINE-1 study examining lasofoxifene in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer harboring estrogen receptor 1 mutations.

Closing out their discussion, Drs Hetty Carraway and Eytan M. Stein highlight an ongoing clinical trial investigating a triplet therapy for AML.

Dr Stein explains clinical trial data on the use of magrolimab plus azacitidine for patients with TP53-mutated AML.

Lauren Welch, MSN, NP-C, AOCNP, describes how she approaches management of patients with NSCLC and known high PD-L1 expression while she waits for pending biomarker testing results.

Zosia Piotrowska, MD, and Michelle Shiller, DO, AP/CP, MGP, explain the frequency of the different biomarkers in NSCLC, and steps clinicians might take to ensure timely and effective molecular testing for their patients.